The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Cancer Policy

Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history

Trump administration and Cornell reach agreement to restore federal research funding

CMS announces GENEROUS drug payment model aimed at lowering Medicaid drug prices

HHS (again) postpones USPSTF meeting

Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients

American Academy of Pediatrics: Leucovorin is not recommended for routine use in autistic children

Clinical Roundup

UAMS study finds digital barriers may limit rural cancer survivors from participating in research

Xilio Therapeutics announces Phase II data for Vilastobart in MSS mCRC

Alliance launches trial to study exercise in cancer patients

Researchers discover gene that could help improve treatment decisions in childhood leukemia

Five genes linked to aggressive prostate cancer in men of African descent, USC study identifies

Some p53 mutations could help fight cancer, Baylor study finds

In The Clinic

Class action complaint alleging GRAIL insider fraud resubmitted after dismissal

Trials & Tribulations
FreeTrials & Tribulations
Regulatory NewsTrials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account